Capitalizing on the momentum of progress
made in rare diseases research over the past six years, the International Rare Diseases Research Consortium (IRDiRC) devised a new set of global rare disease goals for the upcoming decade.
In line with the objectives of the International
Rare Disease Research Consortium (IRDiRC), we aim to develop novel tools that will allow to make more accurate diagnoses, predict the disease course and the efficacy of available treatments, and help developing new and better therapies for rare kidney disea
Rare Disease Research Consortium (IRDiRC), we aim to develop novel tools that will allow to make more accurate diagnoses, predict the disease course and the efficacy of available treatments, and help developing new and better therapies for rare kidney di
Disease Research Consortium (IRDiRC), we aim to develop novel tools that will allow to
make more accurate diagnoses, predict the
disease course and the efficacy of available treatments, and help developing new and better therapies for rare kidney di
disease course and the efficacy of available treatments, and help developing new and better therapies for
rare kidney disea
rare kidney
diseases.
Overall, despite the dramatic therapeutic advances
made elsewhere
in the melanoma field, the poor prognosis of patients with mucosal melanoma mandates continued emphasis on laboratory and clinical
research efforts
in this
rare subset of
disease.